US Senators Probe Health Secretary Kennedy's Ties to $50 Million Merck Vaccine Settlement

A group of U.S. senators is pressing Health and Human Services Secretary Robert F. Kennedy Jr. to clarify whether his family could financially benefit from a recent $50 million legal settlement between Merck & Co. (MRK) and plaintiffs over its Gardasil vaccine. The inquiry, detailed in a letter reviewed by Reuters, raises questions about potential conflicts of interest given Kennedy's past role as an attorney in the litigation and his current position overseeing national health policy.

Conflict of Interest Allegations

In a letter sent Monday, four Democratic senators, including Elizabeth Warren of Massachusetts, formally requested information from Secretary Kennedy. Before joining the administration, Kennedy was an attorney of record in several cases against Merck concerning claims of injury from its Gardasil vaccine for human papillomavirus (HPV).

"You are charged with setting federal vaccine policy and regulating vaccine manufacturers, including Merck, even as your family and former employer may financially benefit from actions you take as Secretary," the letter stated, according to Reuters. The senators have asked for a reply by August 11.

Background on the Financial Stake

Upon his nomination, Kennedy faced scrutiny over his financial ties to the lawsuits. He had initially planned to retain a 10% fee from settlements in cases he referred to the law firm Wisner Baum. After lawmakers raised concerns, Kennedy said he would transfer his financial stake to one of his sons. One of his sons, Conor, is employed at the firm.

Ad

In response to the senators' letter, Brent Weisner, the managing partner of Wisner Baum, stated in an email that "at no time" will Kennedy or his son receive fees from a Gardasil settlement. A spokesperson for the Department of Health and Human Services (HHS) did not immediately respond to a request for comment. Merck has consistently maintained the safety and efficacy of its Gardasil vaccine.

Implications for Vaccine Policy

The senators' questions extend beyond the Merck settlement to broader vaccine policy. They are also inquiring whether Kennedy's department intends to make changes to the Vaccine Injury Compensation Program (VICP), a federal fund administered by HHS that handles claims of vaccine-related injuries.

This development places a spotlight on the intersection of Kennedy's long-held anti-vaccine views and his powerful regulatory role. Any policy changes or perceived conflicts could have significant implications for vaccine manufacturers, public health guidelines, and investor confidence in the pharmaceutical sector.